Basepoint Wealth’s Iovance Biotherapeutics IOVA Stock Holding History

Basepoint Wealth’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$204	Hold	49	–	–	﹤0.01%	618
2026 Q1	$172	Hold	49	–	–	﹤0.01%	637
2025 Q4	$133	Buy	+49	New	+$113	﹤0.01%	593

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Basepoint Wealth's IOVA Position: Q2 2026 in Review

Basepoint Wealth held its Iovance Biotherapeutics (IOVA) position steady in Q2 2026 at 49 shares worth $204. The position accounts for ﹤0.01% of the portfolio, ranked #618.

Basepoint Wealth first reported a position in IOVA in Q4 2025 and has held it in 3 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Basepoint Wealth held 49 shares of Iovance Biotherapeutics worth $204 as of Q2 2026.
Basepoint Wealth left its Iovance Biotherapeutics share count unchanged in Q2 2026.
Iovance Biotherapeutics made up ﹤0.01% of Basepoint Wealth's portfolio in Q2 2026, its #618 holding.
Basepoint Wealth first reported a position in Iovance Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Basepoint Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.